Claire Mazumdar, Chief Executive Officer at Bicara Therapeutics Inc. (BCAX), sold 15,000 shares at $23.61 ($354K) on 2026-04-20, disclosed to the SEC on 2026-04-20.
Scheduled sale ($354k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BCAX | SELL | 2026-05-20 | $301K | — | Filing → |
| BCAX | SELL | 2026-03-20 | $565K | — | Filing → |
| BCAX | SELL | 2026-03-11 | $1.4M | — | Filing → |